Kelsen D P, Bains M, Hilaris B, Chapman R, McCormack P, Alexander J, Hopfan S, Martini N
Cancer. 1982 Mar 15;49(6):1174-7. doi: 10.1002/1097-0142(19820315)49:6<1174::aid-cncr2820490618>3.0.co;2-w.
Sixty-one patients with epidermoid carcinoma of the esophagus have been treated with a three drug combination of cisplatin, vindesine, and bleomycin. Of 53 patients currently evaluable for response, 29 (55%) have had partial remissions: 7/16 with metastatic, and 22/37 with local-regional disease. The median duration of response in metastatic patients is eight months. Of 28 patients treated preoperatively, 23 (82%) had resectable disease. The major toxicities seen were nephrotoxicity and myelosuppression. Cisplatin, vindesine and bleomycin is an effective combination in the treatment of esophageal carcinoma. Effects on long-term survival cannot yet be evaluated.
61例食管鳞状细胞癌患者接受了顺铂、长春地辛和博来霉素三药联合治疗。在目前可评估疗效的53例患者中，29例（55%）获得部分缓解：16例转移性疾病患者中有7例，37例局部区域性疾病患者中有22例。转移性患者的中位缓解持续时间为8个月。在28例术前接受治疗的患者中，23例（82%）疾病可切除。观察到的主要毒性为肾毒性和骨髓抑制。顺铂、长春地辛和博来霉素是治疗食管癌的有效联合方案。对长期生存的影响尚无法评估。
